- Companies
- Veru
Veru Valuation Multiples
Veru is valued at $39M as of November 2026. In the last fiscal year, Veru EBITDA was ($16M).
Veru Overview
About Veru
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Founded
1971
HQ
Employees
20
Website
Financials (Last FY)
EV
$16M
Valuation Multiples
Start free trialVeru Financials
Veru reported last fiscal year revenue of - and negative EBITDA of ($16M).
In the same fiscal year, Veru generated - in gross profit, ($16M) in EBITDA losses, and had net loss of ($23M).
Revenue (LTM)
Veru P&L
In the most recent fiscal year, Veru reported revenue of - and EBITDA of ($16M).
Veru is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
Veru Stock Performance
Veru has current market cap of $39M, and enterprise value of $16M.
Market Cap Evolution
Veru's stock price is $2.29.
Veru share price increased by 4.8% in the last 30 days, and decreased by 7.5% in the last year.
Veru has an EPS (earnings per share) of $-1.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $39M | 8.3% | 4.8% | -18.0% | -7.5% | $-1.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVeru Valuation Multiples
Veru trades at (1.0x) EV/EBITDA.
EV / Revenue (LTM)
Veru Financial Valuation Multiples
As of November 19, 2026, Veru has market cap of $39M and EV of $16M.
Veru has a P/E ratio of (1.6x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Veru Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Veru Margins & Growth Rates
Veru grew net profit by 2% in the last fiscal year.
Veru Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Veru Operational KPIs
Veru's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Veru Competitors
Veru competitors include Cue Biopharma, Neurothera Labs, Aldeyra Therapeutics, Biomea Fusion, Mabion, Coiled Therapeutics, J-Pharma Co, Dogwood Therapeutics, Pliant Therapeutics and Arovella Therapeutics.
Most Veru public comparables operate across Biopharmaceuticals, BioTech, FemTech and SexTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $27M | ($23M) | 0.6x | 1.0x | (0.7x) | - | |||
| $856K | ($4M) | 49.9x | - | (10.5x) | - | |||
| - | ($35M) | - | - | - | - | |||
| - | ($62M) | - | - | (0.2x) | (0.2x) | |||
| $4M | ($13M) | 11.4x | 8.7x | (3.4x) | (4.0x) | |||
| - | ($4M) | - | - | (7.1x) | - | |||
| - | ($9M) | - | - | (2.4x) | - | |||
| - | ($34M) | - | 403.3x | (1.0x) | - | |||
This data is available for Pro users. Sign up to see all Veru competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Veru
| When was Veru founded? | Veru was founded in 1971. |
| Where is Veru headquartered? | Veru is headquartered in United States. |
| How many employees does Veru have? | As of today, Veru has over 20 employees. |
| Who is the CEO of Veru? | Veru's CEO is Mitchell S. Steiner. |
| Is Veru publicly listed? | Yes, Veru is a public company listed on Nasdaq. |
| What is the stock symbol of Veru? | Veru trades under VERU ticker. |
| When did Veru go public? | Veru went public in 1990. |
| Who are competitors of Veru? | Veru main competitors include Cue Biopharma, Neurothera Labs, Aldeyra Therapeutics, Biomea Fusion, Mabion, Coiled Therapeutics, J-Pharma Co, Dogwood Therapeutics, Pliant Therapeutics, Arovella Therapeutics. |
| What is the current market cap of Veru? | Veru's current market cap is $39M. |
| Is Veru profitable? | No, Veru is not profitable. |
| What is the current net income of Veru? | Veru's last 12 months net income is ($25M). |
| How many companies Veru has acquired to date? | Veru hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Veru has invested to date? | Veru hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Veru
Lists including Veru
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




